Corporate

Pfizer signs 20-year lease for new New York City headquarters

Pfizer signs 20-year lease for new New York City headquarters

By

The pharma giant will take up 15 floors of a new Manhattan skyscraper.

Flexion's pivot proves pain-free

Flexion's pivot proves pain-free

By

Clayman says the company's next 18 months are all about Zilretta, with further pipeline construction next up.

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

Day 2 at JP Morgan '18: Pharma's need for more diversity and data sharing grab the spotlight

By

A plea for IT interoperability and a stinging criticism of the pharma industry over its lack of diversity were two highlights of yesterday's events.

Five things for pharma marketers to know: Wednesday, January 10, 2018

Five things for pharma marketers to know: Wednesday, January 10, 2018

By

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

Day 1 at JP Morgan '18: Easier access to cash spells more M&A, say pharma CEOs

By

How drugmakers should prepare for and respond to the forces poised to reshape the industry was a popular topic on day one of the 36th annual JP Morgan Healthcare Conference.

Five things for pharma marketers to know: Tuesday, January 9, 2018

Five things for pharma marketers to know: Tuesday, January 9, 2018

By

Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

Five things for pharma marketers to know: Thursday, January 4, 2018

By

Allergan to cut 1,000 jobs; McKesson acquires RxCrossroads from CVS Health; Pfizer and Sangamo enter collaboration to develop ALS gene therapy

Merck comms head Adele Ambrose to retire

Merck comms head Adele Ambrose to retire

By

VP of investor relations Teri Loxam will take over Ambrose's role in January.

Five things for pharma marketers to know: Thursday, December 14, 2017

Five things for pharma marketers to know: Thursday, December 14, 2017

By

Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business

Five things for pharma marketers to know: Friday, December 15, 2017

Five things for pharma marketers to know: Friday, December 15, 2017

By

FDA approves first topical skin growth treatment; Teva to cut 14,000 jobs; Novartis Oncology CEO resigns

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

Mitsubishi Tanabe's Kevin O'Brien on driving unmet needs

By

The VP of market access at Mitsubishi Tanabe Pharma America discusses driving access and bringing to market the first FDA-approved ALS drug in years.

Ironwood strengthens leadership with two new hires

Ironwood strengthens leadership with two new hires

By

The drugmaker named William Huyett as COO and Gina Consylman as SVP and CFO.

Amarin's Salyer preps for Vascepa push

Amarin's Salyer preps for Vascepa push

By

Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has "a great story to tell, with or without the data."

Five things for pharma marketers to know: Wednesday, December 6, 2017

Five things for pharma marketers to know: Wednesday, December 6, 2017

By

FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data

6 Corporate Pharma Sites that Offer Strong User Experiences

6 Corporate Pharma Sites that Offer Strong User Experiences

It's the experiences we bring to life, rather than the things we create, that build value, gain trust, and earn loyalty.

Five things for pharma marketers to know: Monday, November 27, 2017

Five things for pharma marketers to know: Monday, November 27, 2017

By

Teva to cut thousands of U.S. jobs; Regeneron drops Eylea combo drug development; insurers, drugstores, and hospitals increasingly teaming up

A Road Map for Your Campaign

A Road Map for Your Campaign

Only 2.6% of board members in Standard & Poor's 1,500 firms have marketing experience.

Five things for pharma marketers to know: Tuesday, November 14, 2017

Five things for pharma marketers to know: Tuesday, November 14, 2017

By

FDA approves first digital pill; biotech companies race to develop cancer-fighting microbiome drugs; Loxo and Bayer reach $1.55 billion deal for rare cancer drugs

Maurice Lévy on his 30 years in charge of Publicis Groupe

Maurice Lévy on his 30 years in charge of Publicis Groupe

By

Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."

Front seat to the comms evolution: Abbott's Melissa Brotz

Front seat to the comms evolution: Abbott's Melissa Brotz

By

The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.

10 questions for PhRMA's CEO Stephen Ubl

10 questions for PhRMA's CEO Stephen Ubl

By

Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.

Sanofi asks the world 'How are you?' in latest corporate branding campaign

Sanofi asks the world 'How are you?' in latest corporate branding campaign

By

The Paris-based pharma company debuted a brand campaign and signature last week.

Five things for pharma marketers to know: Tuesday, October 17, 2017

Five things for pharma marketers to know: Tuesday, October 17, 2017

By

J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

Muscular Dystrophy Association taps Lynn O'Connor Vos as CEO

By

The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.

Astellas turns to 'corporate branding 2.0'

Astellas turns to 'corporate branding 2.0'

By

The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.

The professional paths of 8 pharma execs

The professional paths of 8 pharma execs

By

The successes of these pharma execs show that there's no one path to professional bliss.

Memo to New CEOs: Prioritize Diversity

Memo to New CEOs: Prioritize Diversity

By

Management turnover has brought the opportunity to keep up the pressure.

New pharma CEOs to face payer, pricing challenges

New pharma CEOs to face payer, pricing challenges

By

They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.

Why Educating the Board about Your Latest Campaign Matters

Why Educating the Board about Your Latest Campaign Matters

What is second nature to most marketers may not be well understood by healthcare professionals who have spent their careers as physicians, researchers, or caregivers.

Five things for pharma marketers to know: Tuesday, September 5, 2017

Five things for pharma marketers to know: Tuesday, September 5, 2017

By

Novartis CEO Joe Jimenez to step down; Sanofi ends R&D plans for Zika vaccine; oncologists still struggle to predict metastasis